Novo Nordisk Norway AS is part of the global pharmaceutical company Novo Nordisk, which has over 100 years of experience in the treatment of diabetes. The company has expanded its focus to include specialized treatments for haemophilia, obesity, growth hormone deficiency and women's health. With a large international presence, Novo Nordisk has more than 77,000 employees in 80 countries and markets its products in over 170 countries.
The company places great emphasis on sustainability and social responsibility, and works actively to contribute to better health and quality of life for people with chronic diseases. Through its research and development, Novo Nordisk seeks to improve treatment methods and the availability of medicines, while maintaining a commitment to environmentally friendly practices.